Navigation Links
Antifolates show promise against NSCLC subtype
Date:11/13/2011

SAN FRANCISCO Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

"Our findings indicate that when patients with lung cancer have specific changes in the KRAS gene, they become very amenable to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles senior vice president and chief scientific officer of translational research and development, oncology. "This treatment stops the KRAS gene from being expressed in cancer cells and they die because they depend on this gene."

Bacus presented the study results at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

KRAS mutant non-small cell lung cancer (NSCLC) is an "aggressive form of cancer," Bacus said. "Until today, there have been limited treatment options available for those patients."

Bacus and colleagues treated human NSCLC cell lines (KRAS wild type, KRAS mutant nonamplified and KRAS mutant amplified) with the antifolates methotrexate or pemetrexed.

Results showed that KRAS wild-type and KRAS mutant amplified cells were relatively resistant to antifolate treatment. In contrast, antifolates inhibited growth in KRAS mutant nonamplified cell lines. The researchers also discovered a potent downregulation of KRAS gene expression in treated cells. Bacus reported dramatic and prolonged responses to pemetrexed therapy in patients with KRAS mutant NSCLC.

Bacus recommended that oncologists order two tests: one looking for the KRAS mutation and the other to measure KRAS amplification. "Looking at the cancer mutations is not enough; you have to look at gene copies," Bacus said. "It is important before administering very expensive drugs to make sure that those mutations appear."

This study was funded by the Quintiles Translational Research and Development Group; no external funding was used to finance the research.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Blood Thinner Xarelto Shows Promise for Heart Patients
2. Epigenetic therapy shows promise in hard-to-treat lung cancer
3. Vaccine to Treat Breast, Ovarian Cancers Shows Promise
4. Vaccine for metastatic breast, ovarian cancer shows promise
5. New Drug Shows Promise Against Huntingtons Disease
6. Vitamin D, Interferon Alpha Vaccine Show Promise Against Lupus
7. Gene therapy shows promise as hemophilia treatment in animal studies
8. New drug shows promise against multiple sclerosis
9. Fecal Transplants Show Promise for Gastrointestinal Ills
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. New therapy shows promise for treating cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... ... XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s ... Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition similar ... the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Facial plastic ... this holiday season by donating a portion of proceeds to two local organizations: North ... Chicago Animal Control & Friends is a team of authorized and trained volunteers ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million ... suffer from the epidemic of diabetes. 1 However, ... persistently elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... serious complications, including cardiovascular events. If left untreated, hyperglycemia ... and eye disease or blindness. 3 ...
Breaking Medicine Technology: